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Spironolactone and risk of upper gastrointestinal events: population
based case-control study
Katia M C Verhamme, Georgio Mosis, Jeanne P Dieleman, Bruno H Ch Stricker, Miriam C J M Sturkenboom
Abstract
Objective To confirm and quantify any association between
spironolactone and upper gastrointestinal bleeding and ulcers.
Design Population based case-control study.
Setting A primary care information database in the
Netherlands.
Participants All people on the database who were aged 18 or
more between 1 January 1996 and 30 September 2003. Patients
with a history of alcoholism or gastrointestinal cancer were
excluded. Ten controls were matched to each case of
gastroduodenal ulcer or upper gastrointestinal bleeding by age
(year of birth), sex, and index date.
Main outcome measures The occurrence of an upper
gastrointestinal event (bleeding or ulcers), adjusted for potential
confounders with conditional logistic regression analysis.
Results Within the source population of 306 645 patients, 523
cases of gastric or duodenal ulcer or upper gastrointestinal
bleeding were identified and matched to 5230 controls. Current
use of spironolactone was associated with a 2.7-fold (95%
confidence interval 1.2 to 6.0) increased risk of a
gastrointestinal event.
Conclusion The risk of gastroduodenal ulcers or upper
gastrointestinal bleeding is significantly increased in patients
using spironolactone.
Introduction
The incidence of upper gastrointestinal bleeding and ulcers is
decreasing because of better treatment, but patients are still
admitted to hospital because of these conditions.1 Well known
risk factors for upper gastrointestinal bleeding and ulcers are
age, previous upper gastrointestinal bleeding or ulcers, smoking,
alcohol misuse, infection with Helicobacter pylori, and drugs such
as non-steroidal anti-inflammatory drugs, corticosteroids, antico-
agulants, and selective serotonine reuptake inhibitors.2 3 Case
reports indicate a possible association between spironolactone,
an aldosterone receptor antagonist, and upper gastrointestinal
bleeding and ulcers.4 5 One study found that spironolactone may
inhibit the healing of ulcers.6 In that study, spironolactone was
combined with carbenoxolone, an established ulcer healing
drug, to prevent symptoms of pseudo-hyperaldosteronism, a
common adverse effect of carbenoxolone. Ulcer healing was
impaired in patients treated with spironolactone and carbenox-
olone, but not in patients treated with loop diuretics and
carbenoxolone. In another clinical trial, ulcer healing was
impaired when amiloride, a potassium sparing diuretic, was
added to carbenoxolone.7
The mechanism behind the association between spironolac-
tone and upper gastrointestinal events is not well understood,
and the association has never been quantified.We therefore con-
ducted a case-control study in the general population to examine
the association between spironolactone and upper gastrointesti-
nal events (bleeding and ulcers).
Patients and methods
Setting
Our study was conducted within the integrated primary care
information (IPCI) project in the Netherlands. This electronic
database contains information on more than 500 000 patients
registered with 150 general practitioners. The demographic
characteristics of this population are similar to those in the
national registry held by the Central Bureau of Statistics
(www.cbs.nl).
In the Dutch healthcare system, all people are registered with
one general practitioner who acts as a gatekeeper for medical
care and information.8 The electronic records contain coded and
anonymous data on patient demographics, symptoms and diag-
noses (using the International Classification for Primary Care
and free text terminology), clinical findings, referrals, laboratory
findings, and hospitalisations.9 10 Summaries of hospital dis-
charge letters or information from specialists are entered in a
free text format and hard copies can be provided on request.
Information on drug prescription comprises brand name,
amount, strength, indication, prescribed daily dose, and the Ana-
tomical Therapeutic Chemical classification code.11 General
practitioners who participate in the IPCI project are not allowed
to use paper based records. The system complies with European
Union guidelines on the use of medical data for medical research
and is valid for pharmacoepidemiological research.12
Source population
The source population comprised all people aged 18 or more
with at least one year’s valid database history (that is, the practice
had been sending data to the IPCI database for at least one year
and the patient had been registered with the general practitioner
for at least one year). We needed this length of time to have suf-
ficient background information on all participants. Follow-up
started on 1 January 1996 or the date that one year of valid his-
tory was obtained, whichever was latest. We excluded patients
with a history of alcohol misuse or gastric cancer. All participants
were followed from study entry until the first event (gastric or
duodenal ulcer or upper gastrointestinal bleeding), the end of
the study period (September 2003), exclusion, transfer from the
practice, or death, whichever occurred first.
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Identification and validation of cases
The primary outcome was upper gastrointestinal bleeding or a
symptomatic peptic or duodenal ulcer. Cases were all people
with an upper gastrointestinal event confirmed by endoscopy.
We identified potential cases on the computerised records by
searching for International Classification for Primary Care diag-
noses of gastrointestinal bleeding (D14-16), duodenal ulcer
(D85), or peptic ulcer (D86) and by free text searches on
melaena, haematemesis, and ulcer. We excluded bleeding of
oesophageal varices and Mallory Weiss bleeding. The computer-
ised medical records of all potential cases were manually
evaluated by two doctors to exclude false positive records and to
assess the earliest date of onset of each of the events (index date).
Each case was classified as definite (patient with an upper
gastrointestinal event confirmed by endoscopy) or possible
(patient with signs of an upper gastrointestinal event not
confirmed by endoscopy), or was excluded. Doctors were blinded
to exposure to drugs throughout the validation process.
Controls
Up to 10 controls were obtained for each case from the source
population. Controls were followed up at the same time as the
case and we matched them for sex, age (year of birth), and calen-
dar date (index date).
Definition of drug exposure
We retrieved all prescriptions for aldosterone antagonists, loop
diuretics, and amiloride before the index date. Exposure was
classified as “current” if the last prescription covered the index
date or ended within one month before the index date; exposure
was “past” if the period covered by the last prescription ended
between the start of our study and one month before the index
date. We classified participants with no prescription within this
period as non-users. For current users, we studied the effects of
daily dose. Daily doses were expressed as defined daily dose
equivalents.
Covariates
We considered the following conditions as potential confound-
ers: a history of smoking, ischaemic heart disease (angina
pectoris and myocardial infarction), stroke (cerebral bleeding,
ischaemic events, and transient ischaemic attacks), peripheral
artery disease, hypertension, diabetes mellitus, heart failure, pre-
vious upper gastrointestinal events (ulcers or bleeding), and pre-
vious gastritis or oesophagitis.
The following concomitant drugs were taken into account as
covariates: non-steroidal anti-inflammatory drugs, systemic
corticosteroids, platelet aggregation inhibitors (including acetyl-
salicylic acid), anticoagulants, antidepressants, proton pump
inhibitors or histamine 2 receptor antagonists, antacids, and car-
diovascular drugs (digoxin, angiotensin converting enzyme
inhibitors, angiotensin II receptor antagonists, calcium channel
blockers,  blockers,  blockers, and other diuretics).
Statistical analysis
We calculated the incidence of upper gastrointestinal events and
the incidence of first time use of spironolactone by dividing the
number of upper gastrointestinal events and first time users of
spironolactone by the number of person years accumulated by
the study population.
We used conditional logistic regression analysis to assess the
matched unadjusted and adjusted estimates of risk for the asso-
ciation between risk factors and upper gastrointestinal events
and exposure to diuretics and the occurrence of an upper
gastrointestinal event. In the adjusted model we included, one by
one, all covariates that were univariately associated with outcome
(P < 0.05). Risk factors that changed the relative risk of an upper
gastrointestinal event during current use of diuretics by more
than 5% were maintained in the final model.
To estimate the proportion of upper gastrointestinal events
in the total population that can be attributed to current use of
spironolactone, we calculated the population attributable risk
(population attributable risk = attributable risk×proportion
exposed in the population).13 For this calculation, “attributable
risk” was the incidence rate in the exposed population minus the
incidence rate in the unexposed population, and the “proportion
exposed” was the proportion of controls currently using
spironolactone. Data from the Dutch Central Bureau of Statistics
(www.cbs.nl) were used to extrapolate our results to the entire
Dutch population of 18 years or more. We used SPSS 11.5 soft-
ware for all analyses.
Results
Our source population consisted of 306 645 patients who
contributed 1 003 053 person years. We identified 523 definite
upper gastrointestinal events (209 gastroduodenal ulcers and
314 cases of upper gastrointestinal bleeding) and 450 possible
events, resulting in an overall incidence of 9.7 per 10 000 person
years. To avoid false positive misclassification of the outcome, we
only included definite cases in our case-control analyses. For the
523 definite cases, we randomly selected 5230 controls, matched
on index date, age, and sex. The mean age of the cases was 63.4
years (standard deviation 17.5). Cases had a higher prevalence of
previous gastrointestinal bleeding, gastric and duodenal ulcers,
oesophagitis, heart failure, and peripheral artery disease (table
1). Current use of non-steroidal anti-inflammatory drugs,
corticosteroids, antacids, proton pump inhibitors or histamine 2
antagonists, anticoagulants, and platelet aggregation inhibitors
was higher among cases than controls (table 1). A history of
stroke, ischaemic heart disease, and smoking and current use of
antidepressants, calcium channel blockers, angiotensin convert-
ing enzyme inhibitors, and nitrates were also associated with
upper gastrointestinal bleeding or ulcers, but the association was
smaller (odds ratio < 2). During the study period 1717 patients
started taking spironolactone for the first time. The incidence
rate of first time use of spironolactone increased from 0.7 per
1000 person years in 1996 to 3.1 per 1000 person years in 2003.
Current use of spironolactone was associated with a 2.7-fold
increase (95% confidence interval 1.2 to 6.0) in upper
gastrointestinal events (table 2). The association was strongest in
patients taking the higher doses of the drug—a 5.1-fold increase
(1.5 to 17.1) in upper gastrointestinal events was seen with
current use of ≥ 0.5 defined daily dose of spironolactone
compared with no use (table 2). Increasing dosages of loop diu-
retics or amiloride were not associated with upper gastrointesti-
nal bleeding (table 2).
Most patients used spironolactone for heart failure, but some
used it for treatment of hypertension and one used it for liver
cirrhosis. When we stratified patients into those with or without
heart failure, an association was seen between current use of
spironolactone and upper gastrointestinal events in patients
without heart failure. However, when fully adjusted the
association was not statistically significant because of the low
numbers (adjusted odds ratio 4.0, 0.99 to 16.6).
We studied effect modification by ulcerogenic drugs such as
non-steroidal anti-inflammatory drugs, platelet aggregation
inhibitors, corticosteroids, and anticoagulants. As expected, the
association with upper gastrointestinal events was highest for
patients currently taking spironolactone and an ulcerogenic
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drug (7.3, 2.9 to 18.7; table 3). Effect modification was not seen in
patients taking loop diuretics and ulcerogenic drugs (table 3).
We saw no effect modification by sex or age. The duration of
spironolactone use was not associated with outcome (data not
shown).
Finally, on the basis of an incidence rate of upper gastrointes-
tinal events of 25.9 per 10 000 person years among the exposed
source population and 9.6 per 10 000 person years among the
unexposed source population, we calculated a population attrib-
utable risk of 9.3/106/year. Using demographic data from the
Dutch Central Bureau of Statistics and on the basis of an overall
incidence rate of upper gastrointestinal events of 9.7 per 10 000
person years, we calculated that 1% of upper gastrointestinal
events in 2000 could be attributed to the current use of spironol-
actone.
Discussion
Spironolactone was associated with an increased risk of upper
gastrointestinal events. This association was stronger as the dos-
age increased and was most pronounced when spironolactone
was combined with ulcerogenic drugs.
Possible mechanism of action
Aldosterone promotes the formation of fibrous tissue in the
heart and in various other organs by binding to mineralocorti-
costeroid receptors; the effect is modulated by 11 hydroxyster-
oid dehydrogenase enzymes.14 Compounds with
mineralocorticosteroid-like activity also promote tissue repair,
whereas spironolactone inhibits the formation of fibrous
tissue.6 14 15 This inhibition is beneficial in patients with heart fail-
ure and arterial hypertension, as it prevents cardiac fibrosis.15–17
The stomach, and to a lesser extent, the duodenum express min-
eralocorticosteroid receptors and 11 hydroxysteroid dehydro-
genase enzymes, so fibrous tissue formation—via binding of
Table 1 Risk of upper gastrointestinal events according to patient
characteristics.* Values are numbers (%) unless stated otherwise
Characteristic
Cases
(n=523)
Controls
(n=5230)
Adjusted odds ratio
(95% CI)
Comorbidity
History of upper gastrointestinal
bleeding
10 (1.9) 19 (0.4) 5.39 (2.48 to 11.7)
History of gastric or duodenal
ulcer
25 (4.8) 55 (1.1) 4.79 (2.95 to 7.80)
History of oesophagitis 88 (16.8) 378 (7.2) 2.61 (2.02 to 3.36)
Heart failure 53 (10.1) 246 (4.7) 2.54 (1.81 to 3.56)
Peripheral artery disease 21 (4.0) 102 (2.0) 2.13 (1.31 to 3.46)
Current use of other drugs
Non-steroidal anti-inflammatory
drugs
75 (14.3) 261 (5.0) 3.32 (2.49 to 4.42)
Systemic corticosteroids 22 (4.2) 61 (1.2) 3.91 (2.36 to 6.47)
Platelet aggregation inhibitors 111 (21.2) 714 (13.7) 2.16 (1.68 to 2.78)
Anticoagulants 26 (5.0) 132 (2.5) 2.16 (1.40 to 3.33)
Proton pump inhibitors or
histamine 2 antagonists
66 (12.6) 303 (5.8) 2.83 (2.11 to 3.78)
Antacids 7 (1.3) 20 (0.4) 3.52 (1.49 to 8.33)
Diuretics 79 (15.1) 558 (10.7) 1.73 (1.31 to 2.94)
*Only variables with an odds ratio ≥2 shown, except for use of diuretics.
Table 2 Risk of upper gastrointestinal events according to use of
spironolactone, loop diuretics, and amiloride. Values are number (%) unless
stated otherwise
Cases (n=523)
Controls
(n=5230) Odds ratio
Adjusted odds
ratio* (95% CI)
Spironolactone
Never used 506 (96.7) 5176 (99.0) 1.0 1.0
Currently used 13 (2.5) 30 (0.6) 4.6 2.7 (1.2 to 6.0)
<0.5 defined daily
dose
7 (1.3) 21 (0.4) 3.5 1.9 (0.7 to 5.1)
≥0.5 defined daily
dose
6 (1.1) 9 (0.2) 7.3 5.1 (1.5 to 17.1)
Used in the past 4 (0.8) 24 (0.5) 1.8 0.99 (0.3 to 3.1)
Loop diuretics
Never used 465 (88.9) 4906 (93.8) 1.0 1.0
Currently used 31 (5.9) 157 (3.0) 2.2 1.2 (0.7 to 2.0)
<1 defined daily
dose
5 (1.0) 23 (0.4) 2.5 1.7 (0.6 to 4.8)
1 defined daily
dose
15 (2.9) 83 (16) 2.0 1.1 (0.6 to 2.2)
>1 defined daily
dose
11 (2.1) 51 (1.0) 2.4 1.1 (0.5 to 2.4)
Used in the past 27 (5.2) 167 (3.2) 1.8 1.0 (0.6 to 1.7)
Amiloride
Never used 506 (96.7) 5134 (98.2) 1.0 1.0
Currently used 9 (1.7) 53 (1.0) 1.8 1.5 (0.7 to 3.2)
<0.5 defined daily
dose
1 (0.2) 9 (0.2) 1.1 1.2 (0.1 to 9.7)
≥0.5 defined daily
dose
8 (1.5) 44 (0.8) 1.9 1.6 (0.7 to 3.4)
Used in the past 8 (1.5) 43 (0.8) 2.0 1.9 (0.9 to 3.4)
*For spironolactone: adjusted for ischaemic heart disease, history of gastric ulcer, heart
failure, and use of angiotensin converting enzyme inhibitors, nitrates, platelet aggregation
inhibitors, proton pump inhibitors or histamine 2 antagonists, anticoagulants, and other
diuretics; for loop diuretics: adjusted for ischaemic heart disease, heart failure, and use of
angiotensin converting enzyme inhibitors, nitrates, platelet aggregation inhibitors, proton
pump inhibitors or histamine 2 antagonists, anticoagulants, calcium channel blockers,
corticosteroids, and other diuretics; for amiloride: adjusted for stroke and use of calcium
channel blockers, platelet aggregation inhibitors, antacids, nitrates, and other diuretics.
Table 3 Risk of upper gastrointestinal events according to use of
spironolactone and loop diuretics in combination with ulcerogenic drugs.
Values are number (%) unless stated otherwise
Cases
(n=523)
Controls
(n=5230) Odds ratio
Adjusted odds
ratio* (95% CI)
Spironolactone
Never used spironolactone or an
ulcerogenic drug†
188
(35.9)
2718
(52.0)
1.0 1.0
Currently using spironolactone and an
ulcerogenic drug
9 (1.7) 17 (0.3) 10.0 7.3
(2.9 to 18.7)
Currently using spironolactone but
not an ulcerogenic drug
4 (0.8) 13 (0.2) 5.9 3.7
(1.1 to 13.1)
Currently using an ulcerogenic drug
but not spironolactone
176
(33.7)
1024
(19.6)
2.96 2.47
(1.91 to 3.19)
Used spironolactone in the past 2 (0.4) 14 (0.3) 2.7 2.2
(0.5 to 10.3)
Used an ulcerogenic drug in the past 144
(27.5)
1444
(27.6)
1.59 1.37
(1.07 to 1.75)
Loop diuretics
Never used loop diuretics or an
ulcerogenic drug
181
(34.6)
2678
(51.2)
1.0 1.0
Currently using loop diuretics and an
ulcerogenic drug†
21 (4.0) 97 (1.9) 4.23 2.75
(1.50 to 5.04)
Currently using loop diuretics but not
an ulcerogenic drug
10 (1.9) 60 (1.1) 3.32 2.24
(1.04 to 4.81)
Currently using an ulcerogenic drug
but not loop diuretics
164
(31.4)
944
(18.0)
3.12 2.52
(1.94 to 3.28)
Used loop diuretics in the past 14 (2.7) 102
(2.0)
2.74 1.75
(0.91 to 3.38)
Used ulcerogenic drugs in the past 133
(25.4)
1349
(25.8)
1.60 1.39
(1.08 to 1.79)
*For spironolactone: adjusted for gastric ulcer, oesophagitis, heart failure, and ischaemic
heart disease, and use of angiotensin converting enzyme inhibitors, nitrates, proton pump
inhibitors or histamine 2 inhibitors, and other diuretics; for loop diuretics: adjusted for
ischaemic heart disease, heart failure, and use of calcium channel blockers, angiotensin
converting enzyme inhibitors, nitrates, proton pump inhibitors or histamine 2 inhibitors, and
other diuretics.
†Ulcerogenic drugs are non-steroidal anti-inflammatory drugs, platelet aggregation inhibitors,
corticosteroids, and anticoagulants.
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aldosterone to the mineralocorticosteroid receptors—is probably
important in the healing of gastric or duodenal erosions and
ulcers.18 Thus, aldosterone receptor antagonists, such as
spironolactone, could impair the healing of gastric or duodenal
erosions and result in the formation of gastroduodenal ulcers,
with or without bleeding. This could explain why the association
between current use of spironolactone and upper gastrointesti-
nal events is highest in patients also taking an ulcerogenic drug.
Strengths and limitations of our study
Our study had a population based design, so selection bias is
unlikely as all cases and controls came from the same source
population. Information bias is also unlikely, as data were
gathered prospectively without knowledge of the hypothesis
studied. Misclassification of the outcome is probably minimal as
we manually validated all cases and only analysed definite cases,
doctors who classified cases were blinded to the patient’s drug
exposure, and known risk factors for upper gastrointestinal
events appeared as risk factors in our analysis as well. To control
for confounding by indication we adjusted for heart failure, as
one study identified heart failure as a risk factor for bleeding of
peptic ulcers.3 The authors of that study used patients’ self
reports and the concurrent use of diuretics and digoxin to define
heart failure. The association between the different diuretics and
outcome was not studied separately, and part of the association
might be explained by the current use of spironolactone.
Confounding by severity is also possible. Patients with more
severe heart failure are more likely to be treated with spironolac-
tone than those with less severe disease, but they might also have
an inherently higher risk of upper gastrointestinal events.
Increasing dosages of loop diuretics, however, were not
associated with increased risk of upper gastrointestinal events,
but a strong dose-response relation was seen for increasing dos-
ages of spironolactone. Thus, confounding by severity appears
unlikely. In contrast to a previous study, we found no association
or dose relation between amiloride and upper gastrointestinal
events.7 However, in the earlier study patients were given 15 mg
amiloride each day, whereas none of the patients in our study
received more than 5 mg daily.
Conclusions
A Canadian study reported a large increase in prescriptions for
spironolactone after publication of the randomised aldactone
evaluation study, which showed that spironolactone significantly
improves outcomes in patients with severe heart failure.19 We
also found such an increase. On the basis of these observations,
we believe doctors and patients should be informed about the
potential of upper gastrointestinal events when using spironolac-
tone. Spironolactone reduces mortality in patients with sympto-
matic heart failure, and doctors should not refrain from using
this drug in the treatment of these patients. However, we advise
caution and careful follow-up when prescribing spironolactone
to patients at risk of upper gastrointestinal events.
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What is already known on this topic
Individual case reports indicate an association between
spironolactone and upper gastrointestinal events
What this study adds
This population based, case-control study found that
spironolactone was associated with a 2.7-fold increased risk
of upper gastrointestinal events (bleeding or ulcers)
The association increased proportionally with dosage and
was most pronounced when combined with ulcerogenic
drugs
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